Investigating Torsin‐1A‐interacting protein 1 as a predictive and immunological biomarker in cancer

Abstract

BackgroundCancer poses a significant global challenge, and with the projected rise in cancer incidence, there is an urgent need to discover new targets and treatments to improve patient outcomes. Recent advancements in genomics technologies have enhanced our understanding of cancer's complexities and led to the emergence of pan‐cancer analysis as a valuable approach for identifying tumor targets. Torsin‐1A‐interacting protein 1 (TOR1AIP1) is a membrane protein involved in various cellular processes. Emerging evidence suggests its potential involvement in cancer.MethodsIn this study, we conducted a comprehensive analysis of multiple databases to explore TOR1AIP1 expression across different cancer types and stages. We also investigated its correlation with clinical outcomes, such as survival rates and drug sensitivity.ResultsThe results of our analysis showed significant deregulation of TOR1AIP1 expression in multiple cancer types and its association with clinical outcomes, with a particular emphasis on kidney renal clear cell carcinoma. The results of our study highlight the potential predictive value of TOR1AIP1 in cancer prognosis and therapy.ConclusionsThis study establishes a solid foundation and rationale for future experimental investigations, which will contribute to a deeper understanding of the significance of TOR1AIP1 in different cancer types, specifically in kidney renal clear cell carcinoma.

Quantitative proteome analysis of LAP1-deficient human fibroblasts: A pilot approach for predicting the signaling pathways deregulated in LAP1-associated diseases

“…Of note, this association of loss-of-function TOR1AIP1 mutations with the development of nuclear envelopathies [ 13 , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] ], allied to the fact that Tor1aip1 −/− mice display perinatal lethality [ 25 ], is another indicator of the paramount importance of LAP1 for normal cellular functioning. Moreover, it has recently been found that TOR1AIP1 expression is significantly altered in various tumor types [ 26 ] and that LAP1 upregulation can contribute to an enhanced migratory and invasive ability of melanoma cells [ 27 ], which indicates that LAP1 may also be involved in cancer. Altogether, there is considerable evidence pointing to the necessity of deciphering human LAP1 (dys)function.…”